Literature DB >> 29213588

Comparison of the Mini Mental State Examination and depressive symptoms between high cardiovascular risk and healthy community elderly groups.

Amanda Lucas da Costa1,2, Juliana Santos Varela1, Osmar Mazetti2, Luciane Restelatto2, Andry Fitterman Costa2, Claudia Godinho1,3, Ana Luiza Camozzato1, Paulo D Picon2, Márcia L Chaves1,3,4.   

Abstract

The aging of the population is a universal phenomenon with direct consequences upon the public health system. One of the main repercussions of the growth in this sector of the population is the increased prevalence of disorders such as dementia and depression which are very frequent among the elderly. The relationship between cardiovascular risk factors, dementia and depression have been addressed in many recent investigations.
OBJECTIVES: To evaluate the relationship of cognitive performance and depressive symptoms with cardiovascular risk in the elderly.
METHODS: 94 high cardiovascular risk elderly patients and 160 healthy community elderly were evaluated cross-sectionally. The Mini Mental State Examination (MMSE) and the Geriatric Depression Scale (GDS-15) were used as the main measures. The cutoff for presence of depression was 6 on the GDS.
RESULTS: The high cardiovascular risk elderly group showed significantly lower scores on the MMSE (p<0.001) and was significantly associated to depression (p<0.001), independently of education. The logistic regression analysis for depression as the dependent variable, age and group (healthy community or high cardiovascular risk elderly) were kept in the final equation. Higher age (Odds Ratio=0.92; 95% CI 0.86-0.98) and high cardiovascular risk elderly (OR=2.99; 95% CI 1.36-6.59) were associated to depression.
CONCLUSIONS: The present findings corroborate the different cognitive performance of elderly with high cardiovascular risk factors and the association of depressive symptoms with this group.

Entities:  

Keywords:  Mini Mental State Examination; cardiovascular risk; cognitive disorder; depressive disorders

Year:  2008        PMID: 29213588      PMCID: PMC5619083          DOI: 10.1590/S1980-57642009DN20400011

Source DB:  PubMed          Journal:  Dement Neuropsychol        ISSN: 1980-5764


The aging of the population is a universal phenomenon with direct consequences upon the public health system. As life expectancy increases, the number of demented patients worldwide is projected to grow from 24.3 million in 2001 to 81.1 million by 2040.[1] Approximately 6 million Americans and 2 million Brazilians have Alzheimer’s disease.[2,3] AD is the 3rd most expensive disease in USA, after heart disease and cancer, and is among the 10 leading causes of death among people >65 years’ old in developed countries.[2] Therefore, the identification of individuals at risk for developing dementia is essential. Early diagnosis allows therapeutic interventions, decreases families’ level of stress, reduces incidental risk, increases autonomy and maybe in some cases prevents or retards dementia onset.[4] Since depression and dementia are among the most common mental health problems in the elderly population, it is common to observe their comorbid presentation, which impacts quality of life, functional decline, increase in the use of health services, increase of morbidity and mortality.[5] Depression is probably the most frequent cause of emotional distress and worsening of life quality among the elderly.[6,7] This population is more prone to developing depression due to reduced social perspectives, health impo­v­erish­ment, frequent losses, biological, vascular, structural and functional changes, besides neuroendocrine and neurochemistry dysfunction in the brain during aging.[8] Therefore, development of elderly depression is multi-factorial in nature.[5] The association between depression and dementia is also significant. Depressed elderly may present cognitive decline, besides an increased risk for progression to dementia.[9] Over the last 3 decades, a decline of cardiovascular-related mortality has been observed in developed countries, while relatively fast and substantial increases have occurred in developing regions, such as Brazil. According to the World Health Organization, the tendency for increase among developing areas may persist, worsening the scenario of already high morbidity and mortality.[10] The higher risk for developing dementia is found among patients with conditions associated to increased cholesterol levels, such as cardiovascular diseases and atherosclerosis.[11] Studies have been carried out seeking to better understand the role of atherosclerotic disease, dyslipidemia and hypertension, predictive factors of cardiovascular risk, in the development of cognitive deficit. The strong association between atherosclerosis and dementia, especially Alzheimer’s disease, has previously been demonstrated. Patients with vascular disease have shown three-fold higher risk for developing dementia.[12] Prospective studies have shown the relationship of atherosclerotic disease and cognitive decline among the elderly. It is presumed that atherosclerosis may cause neuronal damage through ischemic lesions, followed by inflammatory response that leads to neuronal degeneration. Another hypothesis is neuronal damage caused by hypoperfusion due to decreased blood flow in the brain.[13] A higher frequency of brain ischemic events was found in dementia patients compared to non-demented individuals. In these patients, the observation of atherosclerotic plaques in major vessels presented strong correlation with deposition of neuritic plaques, whose main component is the B-amyloid protein associated to Alzheimer’s disease.[14] However, no association between generalized atherosclerosis and depression in the elderly was observed.[13] The link between dyslipidemia and the occurrence of cognitive deficit has been previously evaluated. The role of higher levels of cholesterol was significant as a risk factor for dementia in middle-age patients, but not among elderly patients.[12] The substantially lower risk of cognitive decline was demonstrated in patients over the age of 50 with the use of statins[15]. Adult hypertension increases the risk of dementia, especially when associated to hypercholesterolemia.[16] Hypertension is associated to increased risk of dementia, and control with anti-hypertensives, mainly with angiotensin converting enzyme inhibitors, has demonstrated a significant reduction in the incidence of dementia.[12] Diabetes is an independent predictor of risk of cognitive decline, and the metabolic syndrome, an important cardiovascular risk factor, plays a role as a predictor of risk for dementia.[17] The association of depression to cardiovascular disease is based on convincing evidence. A bidirectional pathway was proposed for these diseases because depression is an independent risk factor for cardiovascular events, and is more prevalent in patients with these conditions. Depression aggravates vascular disease and is associated to poorer outcomes.[18] The association between risk for cardiovascular events, and cognitive decline and depressive symptoms make screening in this population imperative. The present study aimed to evaluate the relationship of cognitive performance and depressive symptoms with cardiovascular risk in the elderly. The performance on the Mini Mental State Examination and the Geriatric Depression Scale among a sample of dyslipidemic elderly outpatients with high cardiovascular risk and a sample of healthy community elderly was compared.

Methods

A cross-sectional study was carried out for the objectives under investigation. The sample was composed of 94 elderly recruited from the reference center for dyslipidemia and high cardiovascular risk (Centro de Dislipidemia e Alto Risco Cardiovascular) from Hospital de Clínicas de Porto Alegre along with 160 healthy community elderly drawn from a cohort within the catchment area of the same hospital. All participants were aged 60 years or more. Illiteracy was not an exclusion criterion for either of the groups. All patients evaluated at the reference center for dyslipidemia and high cardiovascular risk underwent a detailed clinical examination with an emphasis on past or recent cardiovascular events, physical and neurological examination and laboratory tests. Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, ALT, AST, GGTP, electrolytes, creatinine, uric acid and TSH were the blood tests evaluated. The inclusion criteria for dyslipidemia among the high cardiovascular risk group were based on the clinical guidelines for treatment with statins for this disease developed by the Brazilian Health Ministry.[19] One of the three following criteria (a, b or c) had to be met for inclusion: cholesterol LDL>100mg/dl plus acute myocardial infarction; cholesterol LDL>130mg/dl plus one of the following situations: coronary heart disease evidenced by exercise testing or myocardial scintigraphy, previous myocardial infarction, coronary revascularization, or at least 30% obstruction on coronary angiography; other atherosclerotic disease such as peripheral vascular disease with intermittent claudication or obstruction ≥50% on Doppler, aortic abdominal aneurysm and/or symptomatic carotid disease; diabetes mellitus; genetic syndromes – familial hypercholesterolemia and lipid disorder; higher Framingham score (≥9 for men and ≥15 for women); cholesterol LDL>160mg/dl plus one of the following situations: Framingham score (≥6 for men and =10 for women); age ≥55 years; hypertension; HDL <40 mg/dl; cigarette smoking. Patients with abnormal neurological examination or previous history of stroke and dementia were excluded from this group. All selected patients were using statins regularly. The group of healthy community elderly was drawn from an ongoing cohort study.[20] All selected participants fulfilled criteria for the healthy aging study and consented to participate. The inclusion and exclusion criteria are depicted in Table 1. Briefly, participants underwent a standardized neuropsychological and neurological evaluation. A collateral informant was also used to verify the history. Subjects were excluded if they had age-related diseases or risk factors for cognitive impairment at baseline. All participants and their collateral informants had to report normal functioning in the community at study entry and were screened with the Clinical Dementia Rating scale.[21,22] Participants with a CDR of 0.5 (suggestive of incipient dementia) or greater (suggestive of dementia) were excluded from the sample.
Table 1

Participant selection criteria for the elderly community cohort.

Requirements for entryMajor exclusion criteria
Functionally independentMedical conditions
Gives informed consentMyocardial infarction
Willing to participate in the follow-upDiabetes mellitus
Score=0 on Clinical Dementia Rating ScaleChronic pulmonary disorder
Score >11 on the BlessedChronic renal disease
Information-Memory-Concentration TestHypertension (supine blood pressure >160/95)
 Active cancer
 Seizure disorder
 Stroke/transient ischemic attack
 Parkinson disease
 Other neurological disorders (LAS, MS, etc.)
 Major Surgeries
 Coronary bypass
 Carotid endarterectomy
 Psychiatric conditions (previously diagnosed)
 Schizophrenia
 Major affective disorder
 Phobias
 Chronic anxiety
 Alcohol or drug abuse
 Vision and Hearing
 Vision uncorrectable to 20/100 OU
 Hearing loss (interferes with speech perception)
 Other conditions
 Significant head injury
 Unexplained prolonged loss of consciousness
 Use of medications impairing cognitive function
Participant selection criteria for the elderly community cohort. Demographic data, the Mini-Mental State Examination[23-25] and the Geriatric Depression Scale (GDS-15)[26] were assessed in both groups. Subjects were further categorized into those with or without depressive symptoms according to the cutoff of 6 on the GDS[29] The study was approved by the Ethics Committee for Research of the Hospital de Clínicas de Porto Alegre. All subjects signed an informed consent.

Data analysis

The statistical analysis was performed by the Statistical Package for the Social Sciences (SPSS for Windows 13.0) software. Parametric variables were analyzed with Student’s t test. The Chi-square test (with Yates correction or Fisher exact) was used for the association analysis. One-way ANOVA with covariance analysis and the logistic regression model were used as multivariate models.

Results

Comparison of demographic, MMSE score and presence or absence of depressive symptoms by GDS between the dyslipidemic patients with high cardiovascular risk and the community healthy elderly groups are displayed in Table 2. Education was significantly higher in the healthy community elderly group (p<0.001). The dyslipidemia with high cardiovascular risk elderly group showed significantly lower scores on the MMSE (p<0.001) and was significantly associated to depressive symptoms (p<0.001). On one-way ANOVA with covariance, group (p<0.001) and educational level (p<0.001) showed independent and significant effects on MMSE scores.
Table 2

Demographic and clinical data of high cardiovascular risk group and healthy community elderly group.

VariablesHigh cardiovascular risk elderly with dyslipidemia (n=94)Healthy community elderly (n=160)p
Age (mean ± SD)*66.3±6.267.7±5.80.062
Sex**   
    Female (N %)60 (63.8%)108 (67.5%)0.551
Education (mean ± SD)*2.4±6.496.49±3.39<0.001
MMSE (mean ± SD)*24.24±5.2825.46±3.22<0.001
GDS (depression)**   
    Yes (N %)31 (33%)18 (11.3%)<0.001

Student t test;

Chi-square association test.

Demographic and clinical data of high cardiovascular risk group and healthy community elderly group. Student t test; Chi-square association test. In the multivariate analysis (logistic regression) with depression as the dependent variable, age and group (healthy community or dyslipidemia with high cardiovascular risk elderly) were kept in the final equation (Table 3). Higher age (Odds Ratio=0.92; 95% CI 0.86–0.98) and dyslipidemia among the high cardiovascular risk elderly group (OR=2.99; 95% CI 1.36–6.59) were associated to depression.
Table 3

Logistic regression for depression outcome with age, group (healthy elderly or high cardiovascular risk elderly with dyslipidemia), education, MMSE and sex as independent variables.

VariablesBWaldpOR (95% CI)
Group*1.0967.403.0072.99 (1.36-6.59)
Education-.044.513.4740.96 (0.85-1.08)
Age-.0836.693.0100.92 (0.86-0.98)
MMSE-.0561.643.2000.95 (0.87-1.03)
Sex-.5702.071.1500.56 (0.26-1.23)
Constant5.2914.234.040198.514

High cardiovascular risk elderly with dyslipidemia was the reference group.

Logistic regression for depression outcome with age, group (healthy elderly or high cardiovascular risk elderly with dyslipidemia), education, MMSE and sex as independent variables. High cardiovascular risk elderly with dyslipidemia was the reference group.

Discussion

This study was carried out to analyze both cognitive performance measured by the Mini Mental State Examination (MMSE), and depressive symptoms using the Geriatric Depression scale (GDS) in high cardiovascular risk elderly with dyslipidemia and to compare results with healthy community elderly. We observed lower MMSE scores among the dyslipidemia with high cardiovascular risk elderly as well as greater depression in this group, independently of educational level. Vascular risk factors may impair cognitive functions and are related to the occurrence of not only vascular dementia but also Alzheimer’s disease.[12] The level of evidence for these associations is highest for hypertension and diabetes mellitus(DM), especially when these factors are assessed in middle age.[17,27-29] However, the essential pathophysiological mechanisms were still not linked to clinical relevance.[12] Several studies have highlighted the possible protective effect of antihypertensive therapy on cognition while some trials are assessing the effects of statins and treatments for insulin-resistance.[15,30-33] In the logistic regression for depression controlled for education, both higher age and high cardiovascular risk elderly were risk factors. Elderly with dyslipidemia with high cardiovascular risk presented twice the risk of presenting depressive symptoms than healthy community elderly from the same age group. Emerging evidence has suggested a causal relationship between atherosclerosis and both cognitive decline and depression in old age.[34,35] In addition, neuropathologic findings indicate that subjects with cognitive impairment more often have vascular pathology[36,37], whereas late-life depression has been associated with white matter hyperintensity on brain neuroimaging, assumed to be vascular in origin.[18,38,39] Recognition of the relationship between cerebrovascular disease and depressive symptoms has led to the proposition of the term “vascular depression” to describe a clinical subtype of major depression characterized by apathy, psychomotor changes, and cognitive impairment in the presence of cerebrovascular disease demonstrated on neuroimaging or by focal neurological findings (e.g., mild hemiplegia, facial droop).[9,40] Considering that cognitive decline, dementia and depressive symptoms are a worldwide problem, establishing preventive or curative treatment when available is a major health challenge, and vascular risk factors are a promising research pathway for these conditions.
  38 in total

1.  Midlife blood pressure and dementia: the Honolulu-Asia aging study.

Authors:  L J Launer; G W Ross; H Petrovitch; K Masaki; D Foley; L R White; R J Havlik
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

2.  [Suggestions for utilization of the mini-mental state examination in Brazil].

Authors:  Sonia M D Brucki; Ricardo Nitrini; Paulo Caramelli; Paulo H F Bertolucci; Ivan H Okamoto
Journal:  Arq Neuropsiquiatr       Date:  2003-10-28       Impact factor: 1.420

3.  [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].

Authors:  Andrei C Sposito; Bruno Caramelli; Francisco A H Fonseca; Marcelo C Bertolami; Abrahão Afiune Neto; Aguinaldo David Souza; Ana Maria Pitta Lottenberg; Ana Paula Chacra; André A Faludi; Andréia A Loures-Vale; Antônio Carlos Carvalho; Bruce Duncan; Bruno Gelonese; Carisi Polanczyk; Carlos Roberto M Rodrigues Sobrinho; Carlos Scherr; Cynthia Karla; Dikran Armaganijan; Emílio Moriguchi; Francisco Saraiva; Geraldo Pichetti; Hermes Toros Xavier; Hilton Chaves; Jairo Lins Borges; Jayme Diament; Jorge Ilha Guimarães; José Carlos Nicolau; José Ernesto dos Santos; José Jayme Galvão de Lima; José Luiz Vieira; José Paulo Novazzi; José Rocha Faria Neto; Kerginaldo P Torres; Leonor de Almeida Pinto; Liliana Bricarello; Luiz Carlos Bodanese; Luiz Introcaso; Marcus Vinícius Bolívar Malachias; Maria Cristina Izar; Maria Eliane C Magalhães; Maria Inês Schmidt; Mariléia Scartezini; Moacir Nobre; Murilo Foppa; Neusa A Forti; Otávio Berwanger; Otávio C E Gebara; Otávio Rizzi Coelho; Raul C Maranhão; Raul Dias dos Santos Filho; Rosana Perim Costa; Sandhi Barreto; Sérgio Kaiser; Silvia Ihara; Tales de Carvalho; Tania Leme Rocha Martinez; Waldir Gabriel Miranda Relvas; Wilson Salgado
Journal:  Arq Bras Cardiol       Date:  2007-04       Impact factor: 2.000

4.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 5.  Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions.

Authors:  D C Steffens; K R Krishnan
Journal:  Biol Psychiatry       Date:  1998-05-15       Impact factor: 13.382

6.  Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age.

Authors:  D J Vinkers; M L Stek; R C van der Mast; A J M de Craen; S Le Cessie; J Jolles; R G J Westendorp; J Gussekloo
Journal:  Neurology       Date:  2005-07-12       Impact factor: 9.910

7.  Epidemiologic survey of dementia in a community-dwelling Brazilian population.

Authors:  Emilio Herrera; Paulo Caramelli; Ana Silvia Barreiros Silveira; Ricardo Nitrini
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Apr-Jun       Impact factor: 2.703

8.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

9.  Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.

Authors:  Lawrence S Honig; Walter Kukull; Richard Mayeux
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

10.  Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients.

Authors:  Márcia Lorena Fagundes Chaves; Ana Luiza Camozzato; Cláudia Godinho; Renata Kochhann; Artur Schuh; Vanessa Lopes de Almeida; Jeffrey Kaye
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Jul-Sep       Impact factor: 2.703

View more
  1 in total

1.  Body mass index, cognitive deficit and depressive symptoms in high cardiovascular risk patients.

Authors:  Amanda Lucas da Costa; Juliana Santos Varela; Matheus Roriz Cruz; Andry Fitterman Costa; Paulo Dornelles Picon; Emilio Moriguch; Márcia L F Chaves
Journal:  Dement Neuropsychol       Date:  2010 Oct-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.